Genfit S.A. (GNFT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genfit S.A. (GNFT) has a cash flow conversion efficiency ratio of -0.574x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.10 Million) by net assets ($52.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Genfit S.A. (GNFT) defensive interval to measure how many days the company can operate on defensive assets alone.
Genfit S.A. - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Genfit S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genfit S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genfit S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AME Elite Consortium Bhd
KLSE:5293
|
-0.137x |
|
Al Aqar Healthcare Reit
KLSE:5116
|
0.102x |
|
Soluna Holdings Inc
NASDAQ:SLNH
|
-0.051x |
|
Stellus Capital Investment
NYSE:SCM
|
0.063x |
|
Danal Co. Ltd
KQ:064260
|
-0.042x |
|
TEMC Co. Ltd.
KQ:425040
|
-0.021x |
|
Volati AB
ST:VOLO
|
-0.060x |
|
Cable One Inc
NYSE:CABO
|
0.080x |
Annual Cash Flow Conversion Efficiency for Genfit S.A. (2004–2024)
The table below shows the annual cash flow conversion efficiency of Genfit S.A. from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Genfit S.A. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $69.22 Million | $15.55 Million | 0.225x | +127.54% |
| 2023-12-31 | $67.95 Million | $-55.43 Million | -0.816x | -6.15% |
| 2022-12-31 | $94.53 Million | $-72.64 Million | -0.768x | -191.60% |
| 2021-12-31 | $119.10 Million | $99.92 Million | 0.839x | -85.93% |
| 2020-12-31 | $-16.16 Million | $-96.37 Million | 5.963x | +1151.31% |
| 2019-12-31 | $84.06 Million | $-47.68 Million | -0.567x | +78.82% |
| 2018-12-31 | $20.94 Million | $-56.08 Million | -2.678x | -459.93% |
| 2017-12-31 | $104.23 Million | $-49.86 Million | -0.478x | -150.88% |
| 2016-12-31 | $142.80 Million | $-27.23 Million | -0.191x | +28.95% |
| 2015-12-31 | $55.42 Million | $-14.87 Million | -0.268x | -21.99% |
| 2014-12-31 | $70.43 Million | $-15.49 Million | -0.220x | +66.27% |
| 2013-12-31 | $14.09 Million | $-9.19 Million | -0.652x | +43.31% |
| 2012-12-31 | $6.83 Million | $-7.86 Million | -1.150x | +27.92% |
| 2011-12-31 | $4.46 Million | $-7.11 Million | -1.596x | -148.23% |
| 2010-12-31 | $8.39 Million | $-5.39 Million | -0.643x | -4415.44% |
| 2009-12-31 | $15.52 Million | $-221.00K | -0.014x | +93.83% |
| 2008-12-31 | $22.38 Million | $-5.16 Million | -0.231x | -21.55% |
| 2007-12-31 | $25.37 Million | $-4.81 Million | -0.190x | -202.28% |
| 2006-12-31 | $27.77 Million | $-1.74 Million | -0.063x | -150.16% |
| 2005-12-31 | $13.39 Million | $1.68 Million | 0.125x | -54.99% |
| 2004-12-31 | $14.00 Million | $3.89 Million | 0.278x | -- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more